Evolving therapies for functional colonic disorders

Current Opinion in Gastroenterology

Volumn 12, Issue 1, 1996, Pages 32-38

  Chang, Lin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CISAPRIDE; ELECTROLYTE; FEDOTOZINE; LAXATIVE; OCTREOTIDE; SEROTONIN ANTAGONIST; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; BEHAVIOR THERAPY; CLINICAL FEATURE; COLON DISEASE; COLON MOTILITY; CONSTIPATION; DIARRHEA; DIETARY FIBER; ELECTROLYTE BALANCE; FLUID BALANCE; FLUID RETENTION; HUMAN; HYPNOSIS; INTESTINE TRANSIT TIME; IRRITABLE COLON; PATHOGENESIS; PERCEPTION; PSYCHOTHERAPY; REVIEW; SOCIAL PSYCHOLOGY; VISCERA;

EID: 0029870451     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199601000-00007     Document Type: Review

References (31)

1. Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W: Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989, 2:92-95.
2. McKee DP, Quigley EMM: Intestinal motillty in irritable bowel syndrome: is IBS a motillty disorder? Part 1 : definition of IBS and colonic motility. Dig Dis Sci 1993, 38:1761 -1772.
3. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995, 109:40-52. This study demonstrates that 94% of patients with IBS have altered rectal perception manifested by lowered thresholds for discomfort, increased intensity of sensations, or altered viscerosomatic referral.
4. Mayer EA, Munakata J, Mertz H, Lembo T, Bernstein CN: Visceral hyperalgesia and irritable bowel syndrome. In Visceral Pain: Progress in Pain Research and Management, vol 5. Edited by Gebhart GF. Seattle: IASP Press; 1995:429-468. An extensive review of the functional neuroanatomy of visceral afferents, assessment of visceral hyperalgesia, and the development of central sensitization in IBS.
5. Lembo T, Munakata J, Mertz H, Niazi N, Kodner A, Nikas V, Mayer EA. Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 1994, 107:1686-1696. This study demonstrated that patients with IBS had lowered thresholds to phasic distention rather than ramp distention and that rapid phasic distention preferentially stimulates splanchnic afferents.
6. Mertz H, Lembo T, Sytnik B, Raeen H, Hirsh T, Mayer EA: Rectal afferent mechanisms and symptoms in patients with irritable bowel syndrome [abstract]. Gastroenterology 1993,104:551.
7. Plourde V, Lembo T, Shui Z, Parker J, Mertz H, Tache Y, Sytnik B, Mayer EA: Effects of somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993, 265:G742-G745.
8. Oddsson E, Rask-Madsen J, Krag E: A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978, 13:409-416.
9. Klein KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988, 95:232-241.
10. Snook J, Shepherd HA: Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994, 8:511-514.
11. Poynard T, Naveau S, Mory B, Chaput JC: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994, 8:499-510.
12. Wiseman L, Faulds D: Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994, 47:116-152. This review discusses cisapride's pharmacology, mechanisms of action of the gastrointestinal tract, and its efficacy in functional bowel disorders.
13. Van Outryve M, Milo R, Toussaint J, Van Eeghem P: "Proklnetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991, 13:49-57.
14. Hurlimann S, Shorvon P, Misiewicz JJ: Effects of cisapride on symptoms and ileo-caecal transit In patients with bloated irritable bowel syndrome [abstract]. Gastroenterology 1992, 102:460.
15. Clouse RE, Lustman PJ, Geisman RA, Alper DH: Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994, 8:409-416. This retrospective review made interesting and important observations about the efficacy of low dose antidepressants in the treatment of IBS and the specific IBS patient population that responds to antidepressant medication.
16. Mertz HR, Pass R, Hirsh T, Van-Go F, Mayer EA: Amitryptaline for functional dyspepsia: effect on symptoms, gastric sensitivity and sleep [abstract]. Gastroenterology 1994, 108:649.
17. Hasler WL, Soudah HC, Owyang C: Somatostatin analog inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993, 104:1390-1397.
18. Hasler WL, Soudah HC, Owyang C: Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994, 268:1206-1211.
19. Riviére PJM, Pascaud X, Chevalier E, Le Gallou B, Junien J-L: Fedotozine reverses ileus induced by surgery or peritonitis: action at peripheral κ-opioid receptors. Gastroenterology 1993, 104:724-731.
20. Gué M, Junien J-L, Buéno L: The κ agonist fedotozine modulates colonic distention-induced inhibition of gastric motility and emptying in dogs. Gastroenterology 1994, 107:1327-1334.
21. Dapoigny M, Abitbol JL, Méric G, Genéve J, Fraitag B: Fedotozine in irritable bowel syndrome: results of a 6 wk placebo-controlled multicenter therapeutic trial. Gastroenterology 1995, 108:A588. This clinical trial reported improvement in abdominal pain and quality of life in patients with IBS treated with fedotozine.
22. 3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993, 7:175-180.
23. 3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993, 7:543-551.
24. Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR: Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992, 67:732-738.
25. Svedlund J, Sjödin I, Ottosson J-O, Dotevall G: Controlled trial of psychotherapy in irritable bowel syndrome. A controlled outcome study. Lancet 1983, ii:589-592.
26. Guthrie E, Creed F, Dawson D, Tomenson B: A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991, 100:450-457.
27. Whitehead WE: Biofeedback treatment of gastrointestinal disorders. Biofeedback Self Regul 1992, 17:59-76.
28. Wald A: Approach to the patient with constipation. In The Textbook of Gastroenterology, edn 2. Edited by Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE. Philadelphia: JP Lippincott Co.; 1995:864-880.
29. Grotz RL, Pemberton JH, Talley NJ, Rath DM, Zinsmeister AR: Discriminant value of psychological distress, symptom profiles, and segmental colonic dysfunction in outpatients with severe idiopathic constipation. Gut 1994, 35:798-802.
30. Soffer EE, Metcalf A, Launspach J: Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci 1994, 39:929-933. This is the first published report demonstrating the use of misoprostol for severe chronic constipation.
31. Müller-Lissner SA: Treatment of chronic constipation with cisapride and placebo. Gut 1987, 28:1033-1038.